Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements research observed that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://josefas229tup5.ja-blog.com/profile